Floatz logo

Linsitinib

Hormone-sensitive Metastatic Breast Cancer

Vanderbilt-Ingram Cancer CenterSmall moleculePhase 2Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Hormone-sensitive Metastatic Breast Cancer cohort.

Asset / SponsorPhaseRating
Letrozole
Vanderbilt-Ingram Cancer Center
Phase 2CCC
Panobinostat
Vanderbilt-Ingram Cancer Center
Phase 2CCC
Zoladex
Vanderbilt-Ingram Cancer Center
Phase 2CCC

Same molecule, other indications

Linsitinib is also rated in:

small cell lung carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
prostate adenocarcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
hormone-resistant prostate carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →